- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Synthesis of HCV Protease Inhibitor MK-6325 ; volume:11 ; number:06 ; year:2015 ; pages:0571-0573
Synfacts ; 11, Heft 06 (2015), 0571-0573
- DOI
-
10.1055/s-0034-1380762
- URN
-
urn:nbn:de:101:1-2018102512563886986024
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:35 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Other Objects (12)
Synthesis of a Key Building Block for HCV Protease Inhibitor Telaprevir
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
Synthesis of Renin Inhibitor MK-1597
In silico investigation of HCV and RNA synthesis inhibitor antibiotic drugs as potential inhibitors of SARS‑CoV‑2 main protease (Mpro)
Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors
Synthesis of bacterial protease inhibitors as new antibiotics
Synthesis of HIV Integrase Inhibitor MK-1376
Synthesis of the First FDA-Approved HIV Protease Inhibitor
Design, synthesis and biological evaluation of rhomboid protease specific inhibitors
Design and Synthesis of Allosteric Inhibitors against Dengue Virus Protease
Lysosomotropic agents as HCV entry inhibitors
Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283
Synthesis of a Key Building Block for HCV Protease Inhibitor Telaprevir
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
Synthesis of Renin Inhibitor MK-1597
In silico investigation of HCV and RNA synthesis inhibitor antibiotic drugs as potential inhibitors of SARS‑CoV‑2 main protease (Mpro)
Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors
Synthesis of bacterial protease inhibitors as new antibiotics
Synthesis of HIV Integrase Inhibitor MK-1376
Synthesis of the First FDA-Approved HIV Protease Inhibitor
Design, synthesis and biological evaluation of rhomboid protease specific inhibitors
Design and Synthesis of Allosteric Inhibitors against Dengue Virus Protease
Lysosomotropic agents as HCV entry inhibitors
Implications of hcv natural genetic diversity on HCV NS5B inhibitor NM283
Synthesis of a Key Building Block for HCV Protease Inhibitor Telaprevir
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
Synthesis of Renin Inhibitor MK-1597
In silico investigation of HCV and RNA synthesis inhibitor antibiotic drugs as potential inhibitors of SARS‑CoV‑2 main protease (Mpro)
Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors
Synthesis of bacterial protease inhibitors as new antibiotics
Synthesis of HIV Integrase Inhibitor MK-1376
Synthesis of the First FDA-Approved HIV Protease Inhibitor
Design, synthesis and biological evaluation of rhomboid protease specific inhibitors
Design and Synthesis of Allosteric Inhibitors against Dengue Virus Protease
Lysosomotropic agents as HCV entry inhibitors